Healthcare News | BioTuesdays by Kilmer Lucas IR

Executive Moves

Spartan Bioscience boosts executive team

Closely-held Spartan Bioscience named Blaine Fitzgerald, former VP of finance for Shopify, as CFO. In addition, the company appointed Steve Edgett as EVP to lead its international business development and strategic...

September 5, 2019

Developments

Versant Ventures launches medtech sector investment firm

Versant Ventures launched an independent new venture capital and growth equity investment firm dedicated to the medtech sector. Vensana Capital debuted with the closing of its inaugural fund, Vensana Capital I, with...

September 5, 2019

Markets

Stereotaxis to uplist to NYSE American

The common shares of Stereotaxis (OTCQX:STXS) were approved for listing on the NYSE American exchange, effective with the opening on Sept. 6, with the same stock symbol. They will trade on the OTCQX until the close on...

September 5, 2019

Developments

Aerie Pharma upsizes and prices private sale of $275-million of convertible notes

Aerie Pharmaceuticals (NASDAQ:AERI) priced $275-million principal amount of 1.5% convertible senior notes due 2024. The offering was increased to $275-million from a previously announced size of $250-million. The notes...

September 5, 2019

Developments

Repare Therapeutics raises $82.5-million in Series B financing

Closely-held Repare Therapeutics completed an $82.5-million Series B financing as it prepares to take its lead synthetic lethality therapy into human testing in 2020. Cowen Healthcare Investments led the financing and...

September 4, 2019

Developments

CytoDyn files IND and Phase 2 protocol to treat NASH with leronlimab

CytoDyn (OTCQB:CYDY) filed an IND and a Phase 2 clinical trial protocol with the FDA for the treatment of non-alcoholic steatohepatitis (NASH) with its lead drug candidate, leronlimab. Based on published reports of the...

September 4, 2019

Markets

HCW cuts Tetraphase Pharma to neutral and removes PT

H.C. Wainwright downgraded Tetraphase Pharmaceuticals (NASDAQ:TTPH) to “neutral” from “buy” and removed its price target, citing an early debt payoff that substantially increases the company’s risk. The stock closed at...

September 3, 2019

Developments

Paratek Pharma’s Phase 3 NUZYRA trial results published in The Lancet Infectious Diseases

The results of Paratek Pharmaceuticals’ (NASDAQ:PRTK) Phase 3 trial of NUZYRA for the treatment of acute bacterial skin and skin structure infections (ABSSSI) have been published in the peer-reviewed journal, The Lancet...

August 30, 2019

Developments

Akari gets FDA orphan drug designation for nomacopan

Akari Therapeutics (NASDAQ:AKTX) received FDA orphan drug designation for nomacopan for the treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA) in pediatric patients. HSCT...

August 30, 2019

Markets

AGP starts coverage of Itamar Medical at buy; PT $15.50

Alliance Global Partners initiated coverage of Itamar Medical (NASDAQ:ITMR) with a “buy” rating and $15.50 price target. The stock closed at $9.10 on Aug. 29. “We see Itamar as the technology leader in home sleep...

August 30, 2019

Markets

Stifel ups Tabula Rasa HealthCare to buy; PT to $75 from $70

Stifel upgraded Tabula Rasa HealthCare (NASDAQ:TRHC) to “buy” from “hold” and raised its price target to $75 from $70, citing an “improving risk/reward with a favorable fundamental backdrop.” The stock closed at $57.64...

August 30, 2019

Markets

HCW starts TRACON Pharma at buy; PT $2

H.C. Wainwright launched coverage of TRACON Pharmaceuticals (NASDAQ:TCON) with a “buy” rating and $2 price target. The stock closed at 57 cents on Aug. 29. TRACON is developing targeted therapeutics for cancer...

August 30, 2019

Spartan Bioscience boosts executive team

Versant Ventures launches medtech sector investment firm

Stereotaxis to uplist to NYSE American

Aerie Pharma upsizes and prices private sale of $275-million of convertible notes

Repare Therapeutics raises $82.5-million in Series B financing

CytoDyn files IND and Phase 2 protocol to treat NASH with leronlimab

HCW cuts Tetraphase Pharma to neutral and removes PT

Paratek Pharma’s Phase 3 NUZYRA trial results published in The Lancet Infectious Diseases

Akari gets FDA orphan drug designation for nomacopan

AGP starts coverage of Itamar Medical at buy; PT $15.50

Stifel ups Tabula Rasa HealthCare to buy; PT to $75 from $70

HCW starts TRACON Pharma at buy; PT $2

General

More